A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

NCT07395063 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)

Interventions

DRUG: Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine